BOCOM International Lifts AKESO Price Target to HK$140, Retains "Buy" Rating

Market Watcher
07/15

BOCOM International has raised the target price for AKESO (09926) from HK$115 to HK$140, reaffirming its "buy" recommendation. Near-term catalysts include the overseas submission and comprehensive data release for the HARMONi study, alongside the presentation of AK112-306 research at ESMO 2025. Fourth-quarter reimbursement negotiations for multiple products and indications, as well as progress in ADC and other early-stage initiatives, are also pivotal drivers.

Ivonescimab, developed by AKESO, is accelerating its overseas registration and indication expansion, demonstrating emerging potential as a next-generation immune-oncology cornerstone. The drug's approval outlook abroad appears promising. This year, AKESO launched several Phase III trials in mainland China, addressing high-need patient groups with constrained treatment options. The trajectory for ivonescimab to supplant PD-(L)1 monotherapy as a foundational I/O agent is increasingly evident. Consequently, the PoS-adjusted peak sales forecast for ivonescimab in China has been revised upward to RMB 7.1 billion.

Over the next 2-3 years, assets such as cadonilimab could follow paths to overseas registration or BD deals. Vigilance on data disclosures and clinical program launches is advised.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10